Pfizer-BioNTech vaccine induces immune response in early-phase trial

Pfizer-BioNTech vaccine induces immune response in early-phase trial A Covid-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech firm BioNTech induces a “robust” immune response in healthy adults aged 18–55 years, according to an interim report of an early phase clinical trial, published in Nature on Wednesday. https://ift.tt/eA8V8J